Real-world experience of tralokinumab for atopic dermatitis: A 16-week multicenter retrospective study.

J Am Acad Dermatol

Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Probity Medical Research, Waterloo, Ontario, Canada; Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Division of Dermatology, Department of

Published: May 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2025.01.051DOI Listing

Publication Analysis

Top Keywords

real-world experience
4
experience tralokinumab
4
tralokinumab atopic
4
atopic dermatitis
4
dermatitis 16-week
4
16-week multicenter
4
multicenter retrospective
4
retrospective study
4
real-world
1
tralokinumab
1

Similar Publications

This article explores two complementary strategies for addressing the affordability and access challenges facing advanced therapies. As high development costs and limited market access have led to the withdrawal of several therapies, the article examines how these barriers create 'valleys of death' that prevent innovation from reaching patients. Through the case of Glybera and other examples, it outlines a rehabilitative approach focused on reforming current systems through improved reimbursement schemes, regulatory streamlining, and more efficient manufacturing.

View Article and Find Full Text PDF

Digitally delivered treatment for unusual sensory experiences for people with psychosis: a real-world service evaluation study.

Behav Cogn Psychother

September 2025

Early Intervention in Psychosis Services, Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK.

Background: Hallucinations and other unusual sensory experiences (USE) are common in people with psychosis. Yet access to effective psychological therapies remains limited. We evaluated if we can increase access to psychological therapy by using a brief treatment, focused only on understanding and dealing with hallucinations (Managing Unusual Sensory Experiences; MUSE), delivered by a less trained but more widely available workforce that harnessed the benefits (engaging content, standardisation) afforded by digital technology.

View Article and Find Full Text PDF

The future European Health Data Space (EHDS), a network for secure cross-border data use, could be beneficial for public health initiatives. The HealthData@EU pilot project evaluated possibilities of secondary data use based on five use cases and established a pilot IT infrastructure. This article reports overarching experiences from two public health use cases and the IT development.

View Article and Find Full Text PDF

Background: Self-leadership has been associated with several positive organizational outcomes (e.g., performance and innovation).

View Article and Find Full Text PDF

Background: Trials of neoadjuvant chemoimmunotherapy (chemoIO) have changed the standard of care for resectable nonsmall cell lung cancer (NSCLC). This study characterizes the outcomes of off-trial patients who received treatment with neoadjuvant chemoIO.

Methods: The authors analyzed records of patients with stage IB-III NSCLC who received neoadjuvant chemoIO with an intent to proceed to surgical resection at three US academic institutions.

View Article and Find Full Text PDF